Oral all-trans retinoic acid (atRA) has been shown to reduce the formation of neointimal 26 hyperplasia; however, the dose required was 30 times the chemotherapeutic dose which 27 already has reported side effects. As neointimal formation is a localized process, new 28 approaches to localized delivery are required. This study assessed whether atRA within a 29 citrate-based polyester, poly(1,8 octanediolcitrate) (POC) perivascular membrane would prevent 30 neointimal hyperplasia following arterial injury. atRA-POC membranes were prepared and 31 characterized for atRA release via high performance liquid chromatography with mass 32 spectrometry detection. Rat adventitial fibroblasts (AF) and vascular smooth muscle cells 33 (VSMC) were exposed to various concentrations of atRA; proliferation, apoptosis and necrosis 34
INTRODUCTION 51
Atherosclerosis is the leading cause of death and disability in the United States.(27) Current 52 surgical treatment options include angioplasty with stent placement, endarterectomy, and 53 surgical revascularization. Unfortunately, the long-term durability of these interventions is 54 limited due to the formation of neointimal hyperplasia and vascular remodeling that result in 55 subsequent restenosis.(12; 14; 17; 20-22; 25) While not fully elucidated, both of these 56 processes involve a complex pathophysiologic response of the vasculature to injury. This 57 response affects multiple cell types and results in the proliferation, dedifferentiation, and 58
migration of vascular smooth muscle cells (VSMC) and adventitial fibroblasts (AF).(4; 5) Thus, 59
the ideal therapeutic agent would prevent the dedifferentiation and migration of multiple cell 60 types and have selective effects on the proliferation of endothelial cells versus AF and VSMC. 61
All-trans retinoic acid (atRA), a vitamin A derivative, acts on retinoic acid nuclear receptors 62 regulating cellular proliferation and differentiation.(9) It has been used clinically in patients to 63
treat proliferative disorders such as acute promyelocytic leukemia and other cancers.(10; 29) 64
Furthermore, it has been investigated as a potential agent to inhibit neointimal hyperplasia in 65 animal studies.(7; 13; 23; 31) Specifically, investigators have demonstrated that oral delivery of 66 atRA (10 mg/kg -24 mg/kg) using the rat carotid artery injury model or the atherosclerotic rabbit 67 femoral artery injury model resulted in a reduction of neointimal hyperplasia or positive 68 remodeling following arterial injury.(7; 23; 31) While atRA has been proven to be relatively safe 69 clinically, it is not without systemic effects. The oral doses utilized in these animal studies to 70 achieve efficacy were approximately 30-fold higher than the doses utilized to treat cancer in 71 humans.(8) Furthermore, the systemic doses used in both the animal and human studies have 72 resulted in elevation of both triglycerides and alkaline phosphatase levels.(10; 23) Thus, a safer 73 approach to atRA delivery would be beneficial. re-equilibrate at 70% B. atRA was monitored using both the UV-Vis spectrophotometer at 350 154 nm and mass spectrometer.(16) Quantification was based on the UV-Vis and HPLC-MS peak 155 area of retinoic acid and comparison to a standard curve of known concentration. Since atRA is 156 prone to isomerization, the standard curve also included 9-cis atRA and 13-cis atRA as controls. 157
Samples from the supernatant were collected daily for 2 weeks for atRA concentration 158 measurement (n = 6). 159
Animal surgery 160
All animal procedures were performed in accordance with the Guide for the Care and Use of placed under the common carotid artery (CCA) and wrapped circumferentially 1.5 times aroundthe CCA just inferior to the CCA bifurcation and extending proximally to the inferior border of the 171 sternocleidomastoid muscle. The neck incision was closed in 2 layers, and carotid arteries were 172 harvested 14 days after injury. Groups included injury alone, injury + POC membrane, injury + 173 atRA-POC membrane, and no injury (n = 6 per group). At 2 weeks, the carotid arteries were 174 harvested. The animals were induced with 5% isoflurane via an anesthetic chamber and then 175 maintained on 1.5 to 2.5 % isoflurane via nose cone delivered through a non-breathable circuit. 176
Once the anesthetized as evident by absence of response to toe pinch, the animals were 177 euthanized via a bilateral thoracotomy. After in situ perfusion-fixation with PBS (250 mL) and 178 2% paraformaldehyde (500 mL) via a cannula inserted into the left ventricle the carotid was 179 exposed as previously described and harvested from the inferior border of the 180 sternocleidomastoid muscle to just distal of the carotid bifurcation. The tissue was processed 181 as previously described.(17; 28; 30) 182
Morphometric analysis 183
Specimens were examined histologically for evidence of neointimal hyperplasia using 5-µm 184 hematoxylin and eosin (H&E)-stained cross sections. Six equally-spaced sections from within 185 the area of injury were stained from each animal. Digital images of stained sections were 186 collected with light microscopy using a Zeiss Imager-A2 microscope (Hallbergmoos, Germany). 187
The luminal area, intimal area, medial area, arterial circumference, intima-to-media area ratio 188 (I/M), percent of the arterial wall composed of the intima (intimal area/intimal area + medial area 189 or I/I+M), and percent stenosis (intima area/intimal area + lumen area * 100) were determined 190 using ImageJ software (NIH; Bethesda, MD). 191
Immunohistochemistry 192
The harvested carotid arteries were examined for evidence of inflammation using 193 immunohistochemical staining against ED1, a marker for monocytes and macrophages, or and representative images of each grade were provided to 3 independent, blinded observers to 223 guide their evaluation. The grades within and between reviewers were assessed for intra-and 224 inter-grader consistency. Once grading was completed the slides were unblinded and the 225 difference in the mean grade for the intima, media, adventitia and overall was analyzed with 226 ANOVA on ranks. Images for VCAM-1 staining were converted to CMYK format using Adobe 227
Photoshop CS and the integrated density cumulatively and for the for each layer (intima, media 228 and adventitia) were measured using ImageJ software (NIH; Bethesda, MD), using the method 229 were then summed to calculate the cumulative integrated density for each image. 236
TUNEL Staining 237
To assess atRA-POC effect cell apoptosis in vivo, the harvested rat carotid artery cross sections 238 were stained with the Dead End Colorimetric Terminal deoxynucleotidyl transferase dUTP nick 239 end labeling (TUNEL) system (Promega, Madison, WI), as per the manufacturer's protocol. 240
This process has previously been defined (30). Briefly, sections were washed in 0.85% NaCl, 241 washed in 1x PBS, and fixed in 4% paraformaldehyde. The specimens were rinsed with 1X 242 PBS, treated with 20 µg/ml proteinase K, washed in 1X PBS, and fixed in 4% paraformaldehyde 243 again. The specimens were then washed in 1X PBS and covered with equilibration buffer, then 244 covered with biotinylated nucleotide mix and a plastic coverslip, and incubated for 60 minutes at 245
Page 11 of 28 37°C. The plastic coverslips were removed and the end-labeling reaction terminated by 246 incubation in 2X sodium chloride-sodium citrate for 15 minutes at room temperature. The 247 specimens were then washed 3 times in 1X PBS and blocked for endogenous peroxidases and 248 developed with DAB chromogen as described above. The sections were coverslipped with 249 gevatol and sections were digitally imaged as above. 8 cross sections from each group were 250 stained and counts of the TUNEL positive stained nuclei were collected for the intima, media 251 and adventitial layers and an overall cumulative score was calculated. 252
Statistical analysis 253
To determine the number of animals required in each treatment group to reach statistical 254 significance, a sample size analysis was conducted using an α = 0.05, power of 0.8, difference 255 in means of 0.2, and a standard deviation of 0.1. Analysis revealed that a sample size of 6 for 256 each treatment group was required. All results are expressed as mean ± standard error of the 257 mean (SEM). The difference between two groups was analyzed using Student's t-test while the 258 differences between multiple groups were analyzed using one-way analysis of variance 259 (ANOVA) with the Student-Newman-Keuls post hoc test to assess all pairwise comparisons. 260
Non-parametric data were analyzed using ANOVA on ranks (SigmaStat; SPSS, Chicago,IL). 261
Statistical significance was assumed when P ≤ .05. 262
263

RESULTS
264
Effect of atRA on incorporation of [ 3 H]-thymidine is dependent on concentration and cell type. 265
For rat VSMC we observed a biphasic effect with a slight increase in [ Figure 1B) . 274
To (Figure 2A-B) . VSMC and AF exposed to 50 and 100 μmol/L atRA exhibited minimal 279 early apoptosis, late apoptosis, and necrosis. In fact, levels were similar across all treatment 280 groups. Similarly, the percent of live cells was similar among all treatment groups. Lastly, we 281 analyzed the effect of atRA on cell number. Surprisingly, while there was a trend towards fewer 282 VSMC upon exposure to 100 μmol/L atRA, this did not reach statistical significance. No 283 differences in cell numbers were observed in AF up to 100 μmol/L atRA. These data indicate 284 that while atRA readily reduces [ 3 H]-thymidine incorporation in both VSMC and AF, there is no 285 appreciable effect on cell number, apoptosis or death; however, observations over longer 286 periods of time (e.g., 48, 72, and 96 hours) would likely demonstrate differences in cell number. 287
Periadventitial POC membranes slowly release bioactive atRA for 2 weeks in vitro. atRA (20 288 mg) was loaded onto POC membranes, which released approximately 2 μg of atRA/day during 289 the first week ( Figure 3A) . The total cumulative release over a 2-week time period was 12 µg, of 290 which 92% of the release occurred in the first week. HPLC-MS analysis performed on the 291 supernatant collected from the cumulative release experiments revealed that, when compared 292 with the standard HPLC spectrum for all retinoic acid isomers ( Figure 3B, inset) , atRA was the 293 sole isomer released from the atRA-POC membrane ( Figure 3B ).
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atRA-POC membranes significantly inhibit the formation of neointimal hyperplasia after arterial 295
injury. Balloon injury resulted in the formation of neointimal hyperplasia as confirmed by 296 representative (H&E)-stained cross sections ( Figure 4A ). Only the arteries wrapped with atRA-297 POC showed a significant decrease in neointimal hyperplasia ( Figure 4A ). Morphometric 298 analysis of all samples revealed a 56% decrease in intimal area, 57% reduction in the I/M, in 299 animals treated with the atRA-POC membrane as compared to injury alone (P<.001, Figure  300 4B,C). Consistent with the inhibition of neointimal hyperplasia, we observed a 50% reduction in 301 percent stenosis when compared to injury alone (P<.001, Figure 4E ). We also observed a 15% 302 decrease in luminal area and a corresponding 15% reduction in circumference in the animals 303 receiving POC membranes alone (P<.001, Figure 4D ) as compared to injury alone. 304
Treatment with atRA-POC membranes had no effect on proliferation or apoptosis at 2 weeks. 305
To evaluate the effect of atRA-POC membranes on proliferation, we assessed rat common 306 carotid artery cross sections stained for Ki67. Qualitative grading of these samples 307 demonstrated no differences between treatment groups in the intimal, medial, or adventitial 308 layers (data not shown). Similarly, assessment of carotid cross sections for apoptosis using 309 TUNEL revealed no differences in all layers (data not shown). These findings are not 310 unexpected since the carotid arteries were harvested 2 weeks after injury, a time point when 311 little proliferation and apoptosis is still present. 312
Treatment with atRA-POC membranes decreased macrophage infiltration and VCAM-1 staining 313
in the intimal layer. In order to assess the biocompatibility of the atRA-POC membranes, an 314 assessment of macrophage infiltration was performed. Figure 5A What can be concluded from our ED1 and VCAM-1 investigations is that this anti-inflammatory 474 effect of atRA-POC and POC membranes are favorable and suggests that the material is 475
There are admittedly some limitations of our study. Regarding the in vitro work, the effect of 477 proliferation of atRA was examined only for a period of 18-24 hours which may not have been 478
adequate time point for cell doubling time. We also did not use any additional growth factors to 479 promote proliferation above that of serum. While this is a simplified environment, both our in 480 vitro and in vivo investigations demonstrate that, similar to prior studies, atRA is an effective 481 antiproliferative agent that effectively inhibits neointimal hyperplasia in vivo. Regarding the in 482 vivo work, one weakness in our study is the inability to precisely quantify the amount of atRA 483 delivered to the artery. Another limitation is that we characterized the effect of atRA on 484 proliferation and apoptosis at the 2-week time point. It has been established in the literature 485 that in order to characterize proliferation and apoptosis after arterial injury, early time points 486 ranging from 1 hour to 7 days should be utilized. The 2-week time course is traditionally utilized 487 to assess neointimal formation. Given that our primary end point of interest was to evaluate 488 neointimal hyperplasia, as well as the existing published literature, we did not pursue the earlier 489 time points. A final limitation and an area of future investigation is to elucidate the anti-490 inflammatory mechanisms of the atRA-POC and POC membranes, as this could greatly impact 491 their applications to other biomaterials approaches. that atRA-POC discs continued to release atRA for 2 weeks with maximum release of 12 µg. B) 637
FIGURE LEGENDS 622
Comparison of HPLC curves for various isomers of retinoic acid (RA, inset) with that of the 638 supernatant from atRA-POC discs reveals that atRA is the primary isomer released. 639 Quantification of the (B) intimal area and (C) intima-to-media (I/M) area ratio revealed significant 642 decreases in injured rats treated with atRA-POC membranes, compared to injury alone 643 (*P<.001). Quantification of (D) lumen area and (E) percent stenosis revealed that treatment
